VRAX Stock Overview
A biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Virax Biolabs Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.01 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$0.60 |
| Beta | 1.92 |
| 11 Month Change | -11.84% |
| 3 Month Change | -56.40% |
| 1 Year Change | -15.53% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.90% |
Recent News & Updates
Shareholder Returns
| VRAX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 12.3% | 1.6% | 2.2% |
| 1Y | -15.5% | 2.1% | 31.6% |
Return vs Industry: VRAX underperformed the US Healthcare industry which returned 2.1% over the past year.
Return vs Market: VRAX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| VRAX volatility | |
|---|---|
| VRAX Average Weekly Movement | 21.1% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VRAX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRAX's weekly volatility has decreased from 32% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 17 | James Foster | viraxbiolabs.com |
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual’s immunological profiling data and provide advice on the users’ immune system.
Virax Biolabs Group Limited Fundamentals Summary
| VRAX fundamental statistics | |
|---|---|
| Market cap | US$8.73m |
| Earnings (TTM) | -US$6.58m |
| Revenue (TTM) | US$84.87k |
102.8x
P/S Ratio-1.3x
P/E RatioIs VRAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRAX income statement (TTM) | |
|---|---|
| Revenue | US$84.87k |
| Cost of Revenue | US$51.27k |
| Gross Profit | US$33.60k |
| Other Expenses | US$6.61m |
| Earnings | -US$6.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 39.59% |
| Net Profit Margin | -7,753.22% |
| Debt/Equity Ratio | 2.6% |
How did VRAX perform over the long term?
See historical performance and comparison